Jushi Holdings (JUSHF) Non-Current Debt (2021 - 2026)
Jushi Holdings (JUSHF) posted quarterly Non-Current Debt of $230.0 million for Q2 2026, up 15.05% year-over-year from $199.9 million in Q2 2025, and down 0.59% quarter-over-quarter from $231.4 million in Q1 2026.
Jushi Holdings (JUSHF) Non-Current Debt (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has reported Non-Current Debt for 6 consecutive years, with $230.0 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non-Current Debt rose 15.05% year-over-year to $230.0 million; the TTM figure through Jun 2026 stood at $230.0 million (up 15.05% YoY), while the FY2025 annual figure was $205.8 million, up 10.54% from the prior year.
- Non-Current Debt retreated to $230.0 million in Q2 2026 per JUSHF's latest filing, from $231.4 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $231.4 million in Q1 2026 and bottomed at $61.9 million in Q3 2022.
- Historically, Non-Current Debt has averaged $190.4 million across 5 years, with a median of $202.4 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Debt jumped 242.46% — and 2024, when it declined 12.54%.
- Jushi Holdings' Non-Current Debt stood at $189.3 million in 2022, then climbed by 12.31% to $212.6 million in 2023, then retreated by 12.4% to $186.2 million in 2024, then climbed by 10.54% to $205.8 million in 2025, then climbed by 11.74% to $230.0 million in 2026.
- Business Quant data shows JUSHF's Non-Current Debt at $230.0 million in Q2 2026, $231.4 million in Q1 2026, and $205.8 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | -8.44 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 12.09 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 27.73 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 11.61 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 3.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 130.00 Mn |
| 10 | Jushi Holdings | 83.87 Mn | 50.54 Mn | 31.53 Mn | 230.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 230.00 Mn |
| Mar 31, 2026 | 231.35 Mn |
| Dec 31, 2025 | 205.83 Mn |
| Sep 30, 2025 | 204.58 Mn |
| Jun 30, 2025 | 199.91 Mn |
| Mar 31, 2025 | 196.90 Mn |
| Dec 31, 2024 | 186.21 Mn |
| Sep 30, 2024 | 185.49 Mn |
| Jun 30, 2024 | 202.44 Mn |
| Mar 31, 2024 | 207.06 Mn |
| Dec 31, 2023 | 212.56 Mn |
| Sep 30, 2023 | 212.09 Mn |
| Jun 30, 2023 | 213.43 Mn |
| Mar 31, 2023 | 181.61 Mn |
| Dec 31, 2022 | 189.26 Mn |
| Sep 30, 2022 | 61.93 Mn |
| Jun 30, 2022 | 115.68 Mn |
| Dec 31, 2021 | 119.80 Mn |